Teuza 2025: The Portfolio Still Has Value, but 2026 Will Be Decided by Cash

Getting to Know the Company

Teuza can look, at first glance, like a small listed option on a long-running venture portfolio. That is only part of the story. At a share price of 30 agorot and 113.9 million shares outstanding, the public market is valuing the company at roughly NIS 34 million. On the books, the company carries a fair-value portfolio of $9.952 million and cash of $2.160 million. That gap is what attracts attention, but it is also where the easy mistakes begin.

What is working now is that the portfolio still has two meaningful anchors, Tyto Care and Nano Cell, and Teuza also received a $752 thousand dividend from Segantek in 2025. What is not clean is that the listed parent still depends on limited cash, recurring management fees, and continued support for private companies. Cash fell by $861 thousand in 2025, the company has no profits available for distribution, and after the balance-sheet date it also committed to buy back 23.96 million shares for NIS 9.2 million.

That is why a superficial reading misses the heart of the case. The headline "3% in Tyto" sounds like direct exposure to a company valued at $144.4 million. In practice, Teuza carries that holding at just $2.951 million at year-end 2025, and the appraisal was done using a revenue multiple together with OPM rather than a straight pro rata look-through. The main asset is real, but the value that actually flows into Teuza's layer is lower and more conditional than the headline stake suggests.

The 2026 filter is therefore not leverage but accessible value. This is not a debt-and-covenant story. Current liabilities are only $127 thousand. It is a parent-cash story. If the Bioness settlement gets approved, if Tyto extends its funding runway without damaging value too much, and if Nano Cell starts to look more like a commercial asset than another support line, the read improves. If not, Teuza may continue to hold a portfolio that looks meaningful on paper while the public vehicle itself stays cash-constrained.

The Economic Map of the Portfolio

Events and Triggers

The main point here is that the story in 2026 is no longer just about appraisal marks. It is about the sequence of events that will determine what enters and what leaves the listed parent.

The Legal and Cash Threads Already Sitting on the Company

The first trigger: the Alfred Mann settlement. Teuza committed to purchase 23,957,192 shares from the trustees of Alfred Mann's estate for a total of NIS 9.2 million. Half is due within 90 days of signing and the second half within 6 months. The general meeting already approved the settlement on March 24, 2026, but the transaction still requires court approval for a capital reduction. That matters because the company is not paying out of a comfortable profit pool. It needs a legal route to fund the buyback.

The second trigger: the Bioness settlement. Teuza is leading a U.S. class-action process on behalf of Bioness minority shareholders. Under the proposed settlement, minority holders would receive about $8.9 million gross. Teuza's lawyers estimate the company's share at about $2.8 million, but as of the date the statements were approved, the Delaware court had not yet approved the settlement. This is therefore a meaningful potential inflow, but not yet cash that can be treated as available.

The third trigger: continued funding for Nano Cell. Teuza invested $450 thousand in Nano Cell during 2025 and another $250 thousand after the balance-sheet date. There is also more optionality, or more obligation depending on the lens: Teuza has the right to invest another $400 thousand on the same terms until March 31, 2027. That means the second-largest asset in the portfolio is also one of the clearest future cash calls.

The fourth trigger: Dux has already weakened the initial read on the new investment. After Teuza invested $400 thousand during 2025, the company disclosed after year-end that its epilepsy clinical trial failed and that it is considering a different product direction. This does not break Teuza's thesis on its own, but it is a useful reminder of what an early-stage portfolio really is: a new asset can pivot from promise to reset very quickly.

How the Portfolio Mix Changed in One Year

The chart makes the shift easy to see. Total fair value barely moved, $10.003 million at the end of 2024 versus $9.952 million at the end of 2025, but the internal structure changed materially. Segantek almost disappeared as a value anchor after the dividend, Tyto was marked down, Nano Cell moved up, and Dux entered the picture. This is a portfolio that is becoming more dependent on two private holdings and a thinner set of mature cash-generating assets.

Efficiency, Profitability, and Competitive Read

The central insight is that 2025 looks better than 2024, but not because Teuza suddenly became a self-funding vehicle. What we actually saw was one dividend from Segantek combined with a milder year of write-downs.

What Really Drove 2025

In 2025 Teuza reported revenue of $812 thousand, of which $752 thousand came from the Segantek dividend and $60 thousand from finance income. Expenses came to $2.06 million, including a $1.151 million fair-value loss, $377 thousand of management fees, and $528 thousand of other expenses. Net loss was $1.248 million.

That is meaningfully better than the $3.19 million loss in 2024, but the quality of the improvement matters. The Segantek dividend is largely non-recurring. Segantek paid a $950 thousand dividend in 2025 and was then left with immaterial cash and no operating activity. The single most positive line in Teuza's 2025 income statement therefore came from an asset that has likely exhausted its ability to keep supporting the parent.

The improvement also did not come from a broad turnaround in the portfolio. It came from a smaller fair-value hit. The write-down line fell from $2.547 million in 2024 to $1.151 million in 2025. That is a real accounting improvement, but not cash. If the Segantek dividend is stripped out, Teuza would still have posted roughly a $2.0 million loss even before adding the 2026 pressure points.

Tyto: Better Operating Discipline, Still Not a Funding Solution

The largest portfolio asset tells a two-sided story. On the positive side, Tyto improved some operating metrics. Operating loss narrowed from $24.1 million to $20.5 million, and average monthly cash burn fell from $1.5 million to $925 thousand. On the other side, revenue fell from $24.35 million to $22.5 million, and ending cash dropped sharply from $17.6 million to $6.7 million.

The key question is who paid for the improvement. Tyto's R&D spending fell from $10.9 million to $6.9 million. In other words, part of the better operating-loss and burn profile was purchased through a $4.0 million reduction in R&D, not through stronger revenue. That does not automatically make the improvement low quality, but it does mean the next market test will be whether the company can keep commercial momentum without having weakened the future product engine.

A second issue is disclosure quality. Teuza explicitly says Tyto only provided part of the requested information and refused to disclose additional financial data. For the largest asset in the portfolio, that is a real limitation. The listed parent is marking its biggest holding on partial data and an external valuation, not on a full financial disclosure package.

This is the core paradox. Tyto entered 2026 leaner, but also much less funded. That is why the holding should not be judged in the near term through the notional $144.4 million company valuation alone. It will be judged through the next financing event and through whether the commercial line can stabilize before the July 2026 runway limit that Teuza itself cites.

Portfolio Quality: What Has Value, and What Is Still Below Cost

This chart matters because it reminds the reader that fair value is not the same as accessible value, and not even always the same as capital recovered. Tyto is still carried below cumulative invested capital, Nano Cell is materially below it, and Media Boost is also below cost. Valid.it is a relative positive exception, and Genichek still sits roughly at cost. That does not mean Teuza cannot create a good return from here. It does mean that getting there still requires time, more funding, and actual exits.

Cash Flow, Debt, and Capital Structure

The core point here is that Teuza's balance sheet looks very clean, but that cleanliness can be misleading. There is almost no debt, no covenant pressure, and no refinancing problem. What there is, however, is a limited parent cash layer that still needs to fund the portfolio and absorb post-balance-sheet events.

The Real Cash Bridge

For Teuza, the right framing is all-in cash flexibility, meaning how much cash is left after the period's actual uses of cash. On that basis, the picture is clear. The company started 2025 with $3.021 million of cash. Operating activity used $517 thousand. The company invested $1.1 million into portfolio holdings, partly offset by a $752 thousand dividend from Segantek. After a negligible $4 thousand FX effect, year-end cash came down to $2.160 million.

That matters because 2025 already included a meaningful positive cash event through the Segantek dividend. Even with that help, cash still fell by 28.5%. If that is the cash pattern in a year with a dividend from a legacy holding, it becomes easier to understand why 2026 reads as a bridge year.

No Debt, but Also Not Much Cushion

Current liabilities are only $127 thousand. So this is not a balance-sheet stress story in the classic sense. But focusing only on that would miss the live bottleneck. Management fees alone came to $377 thousand in 2025, around 17% of year-end cash. Other expenses were $528 thousand, including $301 thousand of professional services and $123 thousand of directors' fees. In simple holdco terms, Teuza does not need refinancing, but it does need enough cash so that every corporate event does not become a balance-sheet event.

That read becomes tighter after year-end. Teuza has already approved the Alfred Mann buyback for NIS 9.2 million, and it also put another $250 thousand into Nano Cell. These amounts should not be forced into one number because of currency and timing differences, but they point in the same direction. The public vehicle is not entering 2026 with excess cash.

Value Created Versus Value Accessible

This is the real center of the thesis. On the books, the portfolio is worth $9.952 million. But most of that value sits in private, illiquid assets, and several of them still need capital. Tyto alone is worth $2.951 million and Nano Cell another $2.913 million. Together they make up almost 59% of the portfolio. That is a very high concentration level for a public vehicle of this size.

On the other hand, not every mark translates into cash. Receivables totaled $609 thousand at year-end, including $357 thousand related to a Bioness realization. By contrast, the larger Bioness settlement amount, which Teuza's lawyers estimate at about $2.8 million, is still awaiting court approval. So the market has to distinguish between cash and receivables that are already on the balance sheet, and money that still depends on a legal process.

Outlook

Finding one: 2026 looks like a bridge year at the listed-parent level, not like a harvest year. The company needs to get through the period between funding the Alfred Mann buyback and, potentially, receiving money from Bioness.

Finding two: Tyto is no longer a pure blue-sky telehealth call option. Burn improved, but the company entered 2026 with cash that Teuza says is sufficient only until July 2026. The next financing event is already part of the present thesis, not a distant side note.

Finding three: Nano Cell is no longer a side asset. The move to a $2.913 million carrying value, the investments made during 2025, and the additional investment after year-end mean that Teuza has effectively elevated it into a second pillar. The problem is that this pillar still requires capital.

Finding four: Segantek's dividend made 2025 look better, but it also likely exhausted that source of cash support. If 2026 improves, it will need to come from approved legal inflows, portfolio-company progress, or a new realization event, not from repeating the same dividend engine.

2026 Is a Bridge Year, Not a Breakout Year

Management says Teuza intends to use its available cash to continue supporting portfolio companies and to pursue new investments. That is a reasonable statement, but in 2026 it has a tighter meaning than usual. This is not a year in which the company enjoys wide capital-allocation freedom. It is a year in which it has to prioritize carefully between three competing uses of cash: paying for the buyback, preserving the ability to support existing holdings, and staying open to new opportunities if they emerge.

The more conservative read is that management is trying to buy time. The Bioness settlement could materially improve flexibility, but it is not approved yet. The Alfred Mann settlement could clean up a long-running dispute and simplify the capital structure, but it requires cash before a new exit event has arrived. This is not a solvency problem. It is a question of cash freedom and timing.

What Must Happen at Tyto

For Tyto, the market will likely focus on one issue over the next 2 to 4 quarters: can the company reach its next financing milestone from a better negotiating position. For that to happen, it is not enough that burn is down. Revenue needs to stabilize after the decline in 2025, and the reduction in burn cannot come at the cost of cutting too deeply into the product engine.

The valuation methodology matters as well. Tyto was valued using a revenue multiple together with OPM. That means Teuza's holding is not a simple straight-line exposure to enterprise value. If the next financing round comes on weak terms, both Tyto's headline company value and the portion that actually reaches Teuza's layer can come under pressure together.

What Must Happen at Nano Cell

Nano Cell is probably the rising thread in the portfolio, but it is also a test of Teuza's capital-allocation discipline. Carrying value increased by $500 thousand to $2.913 million in 2025, while Teuza injected $450 thousand during the year and another $250 thousand in early 2026. The question is therefore not just whether Nano Cell is worth more. The question is whether the mark-up is already being supported by enough commercial progress to justify continued follow-on funding.

If Nano Cell starts converting its solar-focused positioning into real commercial traction, it can move from being a cash-consuming option to a second real thesis pillar. If not, Teuza may find itself with two large assets that both require more time and more capital.

What the Market May Measure in the Near Term

Over the next days, weeks, and quarters, the market is unlikely to judge Teuza on theoretical NAV alone. It will judge it through cash events. Court approval or delay around the capital reduction, progress or delay around the Bioness settlement, and any news around financing or commercial traction at Tyto are the kinds of events that can change the market read faster than any fair-value table.

The company's very small listed size makes that even more important. In a vehicle this small, a change in confidence around cash discipline or around the convertibility of private asset value can change the whole reading. At the same time, short-interest data are effectively negligible, so there is no external short pressure telling the story for the market. Investors are effectively being asked to decide whether 2026 can turn two legal processes and two private holdings into a workable cash bridge.

Risks

The central point is that most of Teuza's risks do not sit in debt or rates. They sit in the gap between book value, time, cash, and commercialization.

Heavy Concentration in Private Assets

Tyto and Nano Cell together account for almost 59% of the portfolio's fair value. That is high concentration, especially when both holdings are illiquid and both depend on continued financing or commercial progress. Tyto also comes with a disclosure limitation because the investee provided only partial information. So investors in Teuza are taking not only business risk but also transparency risk.

A Cash Risk, Not a Debt Risk

The absence of debt can create a false sense of comfort. Annual management fees equal to 3% of equity, a 20% success fee on capital gains, ongoing corporate costs, and continued support for portfolio companies all create a relatively steady cash outflow. Inflows, by contrast, are event-driven: dividends, exits, or legal settlements. That kind of structure requires timing discipline, not just a portfolio that looks valuable on paper.

Governance and External-Management Friction

The management agreement is part of the thesis, not a technical footnote. It was extended until December 2028 with no change in terms, and it entitles the management company to annual fees of 3% of equity plus 20% of capital gains on realizations. At the same time, there are ongoing discussions with the Israel Securities Authority staff over how the agreement had been approved in prior periods, and a shareholder has also sought court access to documents related to the agreement. This is not a thesis-breaker by itself, but it is a governance overhang that remains in the background.

Early-Stage Portfolio Risk

Dux has already shown how quickly the read on a new asset can change, with the epilepsy clinical trial failing shortly after the investment. Valid.it, Genichek, and EndoCure also still sit at SAFE, pilot, or development stages. The portfolio is therefore not sitting on a mature asset base that can simply be left alone. It still requires active management and may still require more capital.

Conclusions

Teuza exits 2025 with a portfolio that still deserves attention, but the focal point has changed. It used to be easier to read the company mainly as a listed option on eventual exits. Today the right first lens is parent-level cash. That does not cancel the value in Tyto or Nano Cell, but it does mean the market is likely to judge 2026 through accessible value rather than through gross marked value.

Current thesis: the portfolio still contains real value, but the bottleneck has moved from the holdings layer to the accessible-cash layer.

What changed: Segantek contributed a dividend but is no longer a meaningful value anchor, Nano Cell has become a second portfolio pillar, and a large post-balance-sheet buyback commitment now sits on top of the parent.

Counter-thesis: one can argue that the market is already pricing in the complexity, and that Bioness approval together with one positive event at Tyto or Nano Cell could expose a large gap between the share price and the value embedded in the portfolio.

What may change the market's interpretation in the short to medium term: court approval of the capital reduction, approval of the Bioness settlement, and any signal around financing or commercial progress at Tyto.

Why this matters: in a small public holding company like Teuza, value written into the books is not the same thing as value that can actually reach common shareholders.

What must happen over the next 2 to 4 quarters: Teuza needs to get through the buyback without choking the parent cash layer, gain legal clarity around Bioness, and receive proof from Tyto or Nano Cell that brings realization closer or at least reduces the next capital call.